Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline

This document provides clinical recommendations for the management of severe asthma. Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the European Respiratory Society/American Thoracic Society Task Force's questions. The evidence was appraised using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and the results were summarised in evidence profiles. The evidence syntheses were discussed and recommendations formulated by a multidisciplinary Task Force of asthma experts, who made specific recommendations on six specific questions. After considering the balance of desirable and undesirable consequences, quality of evidence, feasibility, and acceptability of various interventions, the Task Force made the following recommendations: 1) suggest using anti-interleukin (IL)-5 and anti-IL-5 receptor α for severe uncontrolled adult eosinophilic asthma phenotypes; 2) suggest using a blood eosinophil cut-point ≥150 μL−1 to guide anti-IL-5 initiation in adult patients with severe asthma; 3) suggest considering specific eosinophil (≥260 μL−1) and exhaled nitric oxide fraction (≥19.5 ppb) cut-offs to identify adolescents or adults with the greatest likelihood of response to anti-IgE therapy; 4) suggest using inhaled tiotropium for adolescents and adults with severe uncontrolled asthma despite Global Initiative for Asthma (GINA) step 4–5 or National Asthma Education and Prevention Program (NAEPP) step 5 therapies; 5) suggest a trial of chronic macrolide therapy to reduce asthma exacerbations in persistently symptomatic or uncontrolled patients on GINA step 5 or NAEPP step 5 therapies, irrespective of asthma phenotype; and 6) suggest using anti-IL-4/13 for adult patients with severe eosinophilic asthma and for those with severe corticosteroid-dependent asthma regardless of blood eosinophil levels. These recommendations should be reconsidered as new evidence becomes available. The ERS/ATS Task Force makes recommendations on the use of novel therapies for severe asthma, specifically biologicals for type 2 high asthma, and antimuscarinic agents and macrolides, as well as on biomarkers for predicting treatment response http://bit.ly/2kZLRaD

[1]  C. Jenkins,et al.  Long-Term Azithromycin Reduces Haemophilus influenzae and Increases Antibiotic Resistance in Severe Asthma. , 2019, American journal of respiratory and critical care medicine.

[2]  H. Ortega,et al.  Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma , 2019, The Journal of allergy and clinical immunology.

[3]  G. Roberts,et al.  Biologics for paediatric severe asthma: trick or TREAT? , 2019, The Lancet. Respiratory medicine.

[4]  P. O'Byrne,et al.  The interleukin-13 paradox in asthma: effective biology, ineffective biologicals , 2019, European Respiratory Journal.

[5]  W. Busse,et al.  Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma , 2019, European Respiratory Journal.

[6]  Bora study investigators.  Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial , 2019 .

[7]  Ciléin Kearns,et al.  Letting the right one in: evaluating the generalisability of clinical trials , 2018, European Respiratory Journal.

[8]  P. Howarth,et al.  Randomised controlled trials in severe asthma: selection by phenotype or stereotype , 2018, European Respiratory Journal.

[9]  D. Lacombe,et al.  Urgent need for pragmatic trial platforms in severe asthma. , 2018, The Lancet. Respiratory medicine.

[10]  V. Backer,et al.  Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. , 2018, The Lancet. Respiratory medicine.

[11]  C. Brightling,et al.  Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. , 2018, The Lancet. Respiratory medicine.

[12]  P. Dorinsky,et al.  Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial. , 2018, Respiratory medicine.

[13]  K. Chung.  Tralokinumab unsuccessful for management of severe, uncontrolled asthma. , 2018, The Lancet. Respiratory medicine.

[14]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[15]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[16]  M. Humbert,et al.  Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study , 2018, European Respiratory Journal.

[17]  T. Casale,et al.  Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma , 2017, Allergy.

[18]  Richard Beasley,et al.  After asthma: redefining airways diseases , 2017, The Lancet.

[19]  R. Sehmi,et al.  Weight‐adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed‐Dose Subcutaneous Mepolizumab , 2018, American journal of respiratory and critical care medicine.

[20]  A. Boner,et al.  A phase III randomized controlled trial of tiotropium add‐on therapy in children with severe symptomatic asthma , 2017, The Journal of allergy and clinical immunology.

[21]  A. Bush,et al.  Severe asthma: looking beyond the amount of medication. , 2017, The Lancet. Respiratory medicine.

[22]  I. Pavord,et al.  Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.

[23]  D. Shaw,et al.  Strict adherence rules to obtain monoclonal therapy might cost lives. , 2017, The Lancet Respiratory Medicine.

[24]  J. Wedzicha,et al.  Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline , 2017, European Respiratory Journal.

[25]  C. Jenkins,et al.  Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[26]  W. Busse,et al.  A randomized multicenter study evaluating Xolair persistence of response after long‐term therapy , 2017, The Journal of allergy and clinical immunology.

[27]  Todor A Popov,et al.  Blood eosinophil count and exacerbation risk in patients with COPD , 2017, European Respiratory Journal.

[28]  R. Panettieri,et al.  Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review. , 2017, Allergy and asthma proceedings.

[29]  A. Bush,et al.  Intraepithelial neutrophils in pediatric severe asthma are associated with better lung function , 2017, The Journal of allergy and clinical immunology.

[30]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[31]  F. Albers,et al.  Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.

[32]  John R. Hurst,et al.  Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline , 2017, European Respiratory Journal.

[33]  C. Auffray,et al.  T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED , 2017, European Respiratory Journal.

[34]  A. Boner,et al.  A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma , 2017, European Respiratory Journal.

[35]  M. Ebisawa,et al.  Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. , 2017, Allergology international : official journal of the Japanese Society of Allergology.

[36]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[37]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[38]  J. Corren,et al.  Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. , 2016, Chest.

[39]  C. Lemière,et al.  Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. , 2016, Chest.

[40]  E. Bateman,et al.  Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. , 2016, Respiratory medicine.

[41]  E. R. Sutherland,et al.  Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial , 2016, The Lancet.

[42]  Christopher E Brightling,et al.  Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.

[43]  K. Izuhara,et al.  Using Periostin as a Biomarker in the Treatment of Asthma , 2016, Allergy, asthma & immunology research.

[44]  K. Ohta,et al.  A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan , 2016, International Archives of Allergy and Immunology.

[45]  I. Pavord,et al.  Treatable traits: toward precision medicine of chronic airway diseases , 2016, European Respiratory Journal.

[46]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[47]  G. Eberl,et al.  Addressing the experimental variability associated with the microbiota , 2015, Mucosal Immunology.

[48]  M. Levy,et al.  Asthma deaths: what now? , 2015, Thorax.

[49]  L. Edwards,et al.  A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma. , 2015, Respiratory medicine.

[50]  L. Edwards,et al.  The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. , 2015, Respiratory medicine.

[51]  W. Busse,et al.  Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.

[52]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[53]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[54]  S. Walker,et al.  Omalizumab for asthma in adults and children. , 2014, The Cochrane database of systematic reviews.

[55]  British guideline on the management of asthma. , 2014, Thorax.

[56]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[57]  E. R. Sutherland,et al.  Predictors of response to tiotropium versus salmeterol in asthmatic adults. , 2013, The Journal of allergy and clinical immunology.

[58]  S. Spector,et al.  High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. , 2013, The Journal of allergy and clinical immunology.

[59]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[60]  Johny Verschakelen,et al.  Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial , 2013, Thorax.

[61]  Michael Engel,et al.  Tiotropium in asthma poorly controlled with standard combination therapy. , 2012, The New England journal of medicine.

[62]  S. Yale,et al.  Azithromycin for Bronchial Asthma in Adults: An Effectiveness Trial , 2012, The Journal of the American Board of Family Medicine.

[63]  A. Bush,et al.  Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. , 2012, The Journal of allergy and clinical immunology.

[64]  Wu Guo-cheng,et al.  Prevention of COPD Exacerbations , 2012 .

[65]  L. Boulet,et al.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[66]  H. Kerstjens,et al.  Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. , 2011, The Journal of allergy and clinical immunology.

[67]  Martyn R Partridge,et al.  Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. , 2010, The Journal of allergy and clinical immunology.

[68]  Tonya S. King,et al.  A trial of clarithromycin for the treatment of suboptimally controlled asthma. , 2010, The Journal of allergy and clinical immunology.

[69]  A. Evensen.  Management of COPD exacerbations. , 2010, American family physician.

[70]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[71]  C. Sorkness,et al.  Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. , 2008, The Journal of allergy and clinical immunology.

[72]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[73]  R. Scott,et al.  Clarithromycin targets neutrophilic airway inflammation in refractory asthma. , 2008, American journal of respiratory and critical care medicine.

[74]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[75]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[76]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[77]  J Zhang,et al.  What are minimal important changes for asthma measures in a clinical trial? , 1999, The European respiratory journal.

[78]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[79]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.